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Abstract 15 
Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16) are two viruses commonly responsible 16 
for hand, foot and mouth disease (HFMD) in children. The lack of prophylactic or therapeutic 17 
measures against HFMD is a major public health concern. Insect cell-based EV71 and CVA16 18 
virus-like particles (VLPs) are promising vaccine candidates against HFMD and are currently 19 
under development. In this paper, the influence of insect cell line, incubation temperature, and 20 
serial passaging effect of and stability of budded virus (BV) stocks on EV71 and CVA16 VLP 21 
production was investigated. Enhanced EV71 and CVA16 VLP production was observed in Sf9 22 
cells compared to High Five
TM
 cells. Lowering the incubation temperature from the standard 23 
27°C to 21°C increased the production of both VLPs in Sf9 cells. Serial passaging of CVA16 BV 24 
stocks in cell culture had a detrimental effect on the productivity of the structural proteins and 25 
the effect was observed with only 5 passages of BV stocks. A 2.7x higher production yield was 26 
achieved with EV71 compared to CVA16. High-resolution asymmetric flow field-flow 27 
fractionation couple with multi-angle light scattering (AF4-MALS) was used for the first time to 28 
characterize EV71 and CVA16 VLPs, displaying an average root mean square radius of 15 ± 1 29 
nm and 15.3 ± 5.8 nm respectively. This study highlights the need for different approaches in the 30 
design of production process to develop a bivalent EV71 and CVA16 vaccine. 31 
 32 
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1. Introduction 35 
Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16) are structurally similar viruses 36 
belonging to Enterovirus genus of the Picornaviridae family [1]. EV71 and CVA16 are non-37 
enveloped single-stranded RNA viruses, the causative agents of hand, foot, and mouth disease 38 
(HFMD) in children. Enteroviruses could cause severe neurological complications that can 39 
potentially be fatal. The large outbreaks of HFMD in Asia-Pacific regions and the lack of 40 
therapeutics or preventive vaccines against HFMD is a major public health concern [2, 3]. 41 
Moreover, co-circulation and co-infection by both EV71 and CVA16 viruses resulting in 42 
elevated numbers of HFMD infections were reported in China [4]. It was also reported that 43 
individuals vaccinated with EV71 vaccine candidate could still develop HFMD through CVA16 44 
infection [5], confirming that a monovalent EV71 vaccine is not cross protective against CVA16. 45 
Hence, an effective bivalent vaccine against both viruses is needed to prevent HFMD. 46 
Virus-like particle (VLP) vaccines have a proven track record on safety and efficacy, given the 47 
success of VLP-based vaccines against human papillomavir us [6], hepatitis B [7] and hepatitis E 48 
[8]. VLPs are macromolecular structures of viral proteins that are structurally and 49 
immunologically similar to the native virus but they lack the viral genome, thus are non-50 
infectious [9]. Active research to develop VLP-based vaccines against enteroviruses, such as 51 
poliovirus, EV71 and CVA16, is being carried out [10]. 52 
Unlike the licensed single-protein VLP-based vaccines, VLPs of EV71 and CVA16 comprise 53 
multiple proteins and are more complex to produce recombinantly in a heterologous expression 54 
host. The native viruses of EV71 and CVA16 are non-enveloped capsids of icosahedral 55 
symmetry that are 25–35 nm in diameter [11]. The viral genome consists of three polyprotein 56 
regions, where P1 region encodes P1 polyprotein that is proteolytically processed into structural 57 
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proteins VP1, VP3 and VP0 by the 3CD protease encoded within the P2 region. These three 58 
structural proteins spontaneously assemble into a protomer. The protomers assemble into 59 
pentameric intermediates, and 12 pentamers assemble together to form the icosahedral procapsid 60 
structures. This knowledge of the native virus structure and assembly has guided enterovirus 61 
VLP design and production. Simultaneous expression of P1 polyprotein and 3CD protease in an 62 
eukaryotic expression host results in the cleavage of P1 polyprotein into VP1, VP3 and VP0 by 63 
3CD protease [12]. P1 polyprotein is initially cleaved into VP1 and an intermediate product 64 
VP0+VP3 (Figure 1). This intermediate product is further cleaved into VP0 and VP3, leading to 65 
the spontaneous assembly of structural proteins into protomers, then to pentamers and finally 66 
into VLPs. 67 
Following the success of insect cell-based Cervarix® (GSK) HPV VLP vaccine and FluBlok® 68 
(Protein Sciences Corporation) influenza vaccine, baculovirus expression system (BEVS) has 69 
become a commercially viable platform for vaccine production [13]. BEVS also allows efficient 70 
expression of multiple proteins simultaneously making it a powerful and popular platform for 71 
multi-protein VLP production [14, 15]. However, the structurally complex multi-protein EV71 72 
and CVA16 VLPs bring in different production challenges [10]. 73 
In this work, the influence of insect cell line, expression temperature, serial passaging effect and 74 
storage stability of virus stocks on EV71 and CVA16 VLP production were investigated. The 75 
potency and safety of VLP-based vaccines are largely dependent on their biophysical properties, 76 
hence accurately characterizing the structural integrity of the VLPs is critical [16]. In this study, 77 
for the first time, asymmetric flow field-flow fractionation (AF4) with multi-angle light 78 
scattering detection was used for biophysical characterization of insect cell-based EV71 and 79 
CVA16 VLPs. 80 
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2. Materials and methods 81 
2.1 Construction of transfer vectors  82 
Human EV71 (SB12736-SAR-03) and CVA16 (SB3512/SAR/00) VLP cassettes (P1-EMCV 83 
IRES-3CD) were synthesized by DNA2.0 and subcloned into the Gateway® destination vector 84 
pDEST
TM 
8 by attL/attR in vitro recombination using LR Clonase® from Life Technologies 85 
(CA, USA).  86 
2.2 Cells and virus 87 
Spodoptera frugiperda (Sf9) and Trichoplusia ni (High Five
TM
) insect cell lines were cultured in 88 
Sf-900
TM
 II serum-free media (SFM) (Life Technologies). Cells were maintained in suspension 89 
at mid-log phase and incubated at 27
o
C in a shaking incubator set at 120 rpm. 90 
The recombinant Autographa californica multiple nucleopolyhedrovirus (AcMNPV) baculovirus 91 
for expression of the P1 polyprotein and 3CD protease under the control of polyhedrin promoter 92 
was constructed by transformation of pDEST™ 8 constructs into DH10BacTM competent cells 93 
according to the Bac-to-Bac® (Life Technologies) manufacturer’s manual. Recombinant 94 
bacmids (Bac-P1-3CD) were isolated for insect cell transfection. Sf9 cells in Sf-900
TM
 II SFM 95 
were seeded at 2.4 x 10
5
 cells/well in a 24-well microtitre plate. For optimal transfection, 96 
Cellfectin® II reagent (Life Technologies) was added to 200 ng of recombinant bacmid DNA 97 
and incubated at room temperature for 30 min before dispensing onto adherent Sf9 cells. The 98 
transfected cells were incubated at 27°C for 5 h before replacing with fresh Sf-900
TM
 II SFM. 99 
After 7 days, spent culture medium containing passage 1 recombinant baculovirus (known as 100 
budded virus, BV) was harvested. The harvested virus stock was used as inoculum to initiate 101 
subsequent virus amplification. Sf9 cells (1 x 10
6
 cells/mL) were infected with passage 1 BV 102 
stock at an estimated multiplicity of infection (MOI) of 0.1. The culture was incubated at 27
o
C 103 
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and the cell density and viability were monitored using a Countess® automated cell counter (Life 104 
Technologies) using the 0.2% trypan blue exclusion method. Passage 2 BV stock was harvested 105 
from the culture by centrifugation at 1,500 x g for 5 min to remove cells. Virus titers of BV 106 
stocks were estimated based on the viable cell size method [17]. 107 
2.3 Expression Screen 108 
Passage 4 expression was set up with both Sf9 and High Five
TM
 cells cultured in Sf-900
TM
 II 109 
SFM at mid-log phase (3 x 10
6
 cells/mL and 1.5 x 10
6 
cells/mL, respectively). The cells were 110 
infected with passage 3 BV stocks at an estimated MOI of 5. The cultures were incubated at 111 
27°C or 21°C in a shaking incubator set at 120 rpm. Cell densities and viabilities were monitored 112 
as described above. Both cells and supernatant were collected every 24 h for Western blot 113 
analysis.  114 
2.4 Serial Passaging 115 
Budded virus was continuously serial passaged up to passage 8 to obtain BV stocks for 116 
expression at Passage 4 to Passage 9. Sf9 cells in Sf-900
TM
 II SFM were infected with BV stocks 117 
from passage 4 to passage 8 at an estimated MOI of 5 and cultured at 27
o
C. Cell densities and 118 
viabilities were monitored daily and samples were collected for Western blot analysis. 119 
2.5 Stability of BV stocks 120 
The stability of Passage 3 BV stocks of EV71 and CVA16 were examined by comparing 121 
expression between newly amplified BV stocks, BV stocks stored at 4
o
C or -80
o
C for 4 months. 122 
Sf9 cells (3 x 10
6 
cells/mL) were infected with Passage 3 BV stocks at an estimated MOI of 5 at 123 
21°C and expression was analyzed by Western blot. 124 
2.6 Expression and purification of EV71 and CVA16 VLPs 125 
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EV71 and CVA16 VLPs were expressed in Sf9 cells in Sf-900
TM
 II SFM at 21
o
C for 120 h. 126 
Expression culture was harvested by centrifugation at 8,000 x g for 20 min and the cells and 127 
supernatants were collected separately for purification. The cell pellet was resuspended in lysis 128 
buffer (20 mM NaH2PO4, 500 mM NaCl, pH 7.5) and disrupted using a Sonifer® Cell Disrupter 129 
with a 1/2” titanium horn (Branson® Ultrasonics, NC, USA). Cell debris was removed by 130 
centrifugation at 15,000 x g for 30 min. VLPs in the clarified soluble fraction were recovered by 131 
ammonium sulphate ((NH4)2SO4) precipitation at 20% saturation for 30 min at room 132 
temperature. The precipitated VLPs were pelleted by centrifugation at 10,000 x g for 10 min and 133 
resuspended in 20 mM Tris, 50 mM NaCl, pH 7.5 before loading onto a Capto™ Core 700 134 
column (CV 4.7 mL) (GE Healthcare Life Sciences, Uppsala, Sweden) at 1 mL/min flow rate in 135 
a flow-through mode purification. 136 
For purification of VLPs from the extracellular fraction, culture supernatant was first filtered 137 
using a 0.45 μm filter. The filtered supernatant was 10 times concentrated with a tangential flow 138 
filtration (TFF) unit with a 300 kDa nominal molecular weight cut-off (MWCO) ultrafiltration 139 
cassette (Sartorius AG, Goettingen, Germany) and buffer exchanged into 20 mM Tris, 50 mM 140 
NaCl, pH 7.5. The retentate material was centrifuged at 16,500 x g for 15 min at 4
o
C to remove 141 
particulates before being loaded onto a Capto™ Core 700 column (CV 4.7 mL) in a flow-142 
through mode purification at 1 mL/min flow rate.  143 
2.7 Western blot analysis 144 
The VLP samples were analyzed on a 12% SDS-polyacrylamide gel electrophoresis (PAGE) 145 
under reduced and denatured conditions. The SDS-PAGE gel was transferred onto PVDF 146 
membrane using iBlot® Western blotting system (Life Technologies) and probed with the 147 
appropriate primary antibody (rabbit anti-EV71-VP1 polyclonal sera that cross-reacts with 148 
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CVA16 VP1, rabbit anti-EV71-VP0 polyclonal sera or rabbit anti-CVA16-VP0 polyclonal sera) 149 
at a dilution of 1:4,000 and followed by the secondary antibody (HRP-conjugated goat anti-150 
rabbit IgG) at a dilution of 1:15,000. Chemiluminescent signals were developed using ECL 151 
chemiluminescent substrate reagent kit (Life Technologies) and visualized on a Chemi-Doc
TM
 152 
XRS+ imaging system (Bio-Rad Laboratories, Inc., CA, USA).   153 
2.8 Asymmetric flow field-flow fractionation analysis 154 
Asymmetric flow field-flow fractionation (AF4) analysis was performed as per previously 155 
described [18], with some modifications. Briefly, the injected samples were focused for 6 min at 156 
the marrow injection point. The detector flow through the downstream of detectors was 157 
maintained at 1.2 mL/min. At the end of the focus mode, the analytes were eluted under a 158 
constant cross flow of 1 mL/min for 30 min, after which the cross flow rate was decreased 159 
stepwise to zero for the elution of highly retained analytes. The AF4 analysis was performed 160 
using an Eclipse® 3+ system (Wyatt Technology Corporation, CA, USA) coupled with SPD-161 
20A UV/Vis detector (Shimadzu, Kyoto, Japan) and a DAWN Heleos II multi-angle light 162 
scattering detector (MALS, Wyatt Technology Corporation). The AF4 system was equilibrated 163 
with 50 mM Tris-Glycine, 150 mM NaCl, pH 7.4 prior to analysis. VLP samples were 164 
centrifuged (16,500 x g, 4°C, 15 min), and 100 μL of the supernatant was injected into AF4 and 165 
fractionated. Data acquisition and analysis were formed using the Astra® V software (Version 166 
5.3, Wyatt Technology Corporation). Immunoaffinity chromatography purified EV71 VLPs 167 
(supplied by Sentinext Therapeutics) was used as a standard for initial AF4 method development. 168 
2.9 Transmission electron microscopy analysis 169 
Transmission electron microscopy (TEM) was performed using 5 μL of purified VLP sample 170 
applied to a Formvar coated, 200-mesh copper grid, rinsed with water, and stained with 1% w/v 171 
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uranyl acetate. Sample grids were analyzed with a JEOL 1010 (JEOL, Tokyo, Japan) microscope 172 
at 100 kV and the electron micrographs were recorded using a Morada camera (Olympus® Soft 173 
Imaging System GmbH). 174 
3.  Results and discussion 175 
3.1 Effect of temperature and cell line  176 
The expression of EV71 and CVA16 was tested in two commonly used insect cell lines, Sf9 and 177 
High Five™, and at incubation temperatures of either 21°C or 27°C. Both cells and supernatant 178 
were collected every 24 h for the detection of viral structural proteins. Figure 2A shows the 179 
Western blot analysis of the intracellular and extracellular fractions with anti-EV71-VP1 180 
antibodies. The anti-EV71-VP1 antibody could detect EV71 P1 polyprotein (VP0+VP3+VP1, 96 181 
kDa) and VP1 structural protein (33 kDa). However, in the CVA16 cultures, this antibody 182 
detected only CVA16 VP1 structural protein and no CVA16 P1 protein was detected. Non-183 
specific antibody binding was not observed in the uninfected cell samples. 184 
At 27°C, both Sf9 and High Five™ cell lines showed similar levels of EV71 VP1 inside the 185 
cells, peaking at 48 hours post infection (hpi). Protein degradation was observed in High Five™ 186 
but not in Sf9. At the same temperature, significantly more VP1 was detected in the Sf9 187 
extracellular fraction compared to High Five™. It is unclear if the level of VP1 detected reflects 188 
the accumulation of assembled VLPs. The mechanism for trafficking of enterovirus VLPs to the 189 
extracellular fraction after intracellular assembly is unknown. CVA16 VP1 production was 190 
significantly lower under all conditions when compared to EV71. In the extracellular fractions, 191 
CVA16 VP1 degradation was observed in both cell lines, while similar degradation in the 192 
intracellular fraction was observed only in High Five
TM 
cells. At 27°C, the optimum cell line for 193 
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CVA16 VLP production was Sf9 cells and the optimum time of harvest (TOH) was 48 hpi and 194 
72 hpi for intracellular and extracellular VLPs, respectively (Figure 2A).  195 
The incubation temperature was lowered to 21°C to investigate if a lower temperature could 196 
prolong cell viability, thus delay cell lysis and allow higher production and/or processing of P1 197 
polyprotein to VP1. EV71 VP1 production (intracellular and extracellular) was enhanced in Sf9 198 
cells, suggesting that the P1 polyprotein cleavage to VP1 was more efficient at 21°C than at 199 
27°C. The reduction in temperature did not have a significant effect on VP1 production in High 200 
Five™. The optimum TOH for intracellular EV71 VLPs in Sf9 was 96 hpi and extracellular 201 
EV71 VLPs in Sf9 was 120 hpi (Figure 2A). At 21°C, an increase in CVA16 VP1 production 202 
was observed in Sf9 but not in High Five
TM
, similar to EV71. For Sf9 cell line, the optimum 203 
TOH for intracellular CVA16 VLPs was 96 hpi, and 144 hpi for extracellular CVA16 VLPs. 204 
To determine CVA16 P1 polyprotein processing, CVA16 samples were also analyzed with anti-205 
CVA16-VP0 antibody Western blot. Figure 2B shows the proteolytic cleavage of P1 polyprotein 206 
into intermediates (corresponding to VP0+VP3, 63 kDa) and VP0 (37 kDa). Consistent with the 207 
results obtained for anti-EV71-VP1 antibody Western blot analysis, 21°C is the optimal 208 
temperature for CVA16 expression and highest level of VP0 was detected at 144 hpi in the 209 
extracellular fraction at this temperature (Figure 2B). 210 
EV71 and CVA16 VLPs are structurally similar but significant differences in protein yield and 211 
site of protein accumulation were observed when produced in insect cells. Choice of cell line has 212 
previously been reported to have an effect on level of expression of foreign genes in the 213 
baculovirus-insect cell system [19]. In this study, enhanced production of EV71 and CVA16 214 
VLPs were observed in Sf9 cells compared to High Five
TM
 cells. This result is consistent with 215 
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the report by Chung and coauthors describing different approaches to production of EV71 VLPs. 216 
They also showed higher yields in Sf9 cells than in High Five
TM
 cells and suggested that this 217 
could be due to the cellular and genetic differences of the two cell lines [20].  218 
The baculovirus-insect cell system is a powerful system for recombinant protein expression [21]. 219 
However, as a lytic viral expression system, cell lysis-associated proteolysis is a major drawback 220 
[22]. Culture temperature and pH are key factors that can influence proteolytic activity and 221 
product quality in the baculovirus-insect cell system [23]. Previous studies have shown that 222 
lowering the incubation temperatures from 28°C or 30°C to 20°C increased recombinant protein 223 
production yield in insect cells [24, 25]. Rapid depletion of oxygen in cultures was observed at 224 
elevated temperatures [26]. Such increases in the respiratory and metabolic activity at elevated 225 
temperatures often increases the rate of cell death and terminates recombinant protein production 226 
[27]. Premature termination of P1 polyprotein and/or 3CD protease production at high 227 
temperature would affect P1 polyprotein processing into structural proteins (VP0, VP3 and VP1), 228 
a pre-requisite to spontaneous VLP assembly. Production of VLPs using the baculovirus-insect 229 
cell system at 21°C may have slowed down cell metabolic activity, thus delaying cell lysis and 230 
prolonging the life span of infected cells to allow structural protein processing and maturation of 231 
VLPs in the cells. 232 
3.2 Effect of serial passaging on expression 233 
The effect of serial passaging BV stocks on the production of EV71 and CVA16 VLPs was 234 
investigated in Sf9 cells at 27°C. Structural protein production analyzed on Western blots probed 235 
with anti-EV71-VP1 antibody (Figure 3A) indicated that there was a significant drop in CVA16 236 
VP1 production after 5 passages of BV stocks in cell culture. In contrast, EV71 VP1 production 237 
was detected for at least 9 passages, although a gradual decrease in VP1 production was 238 
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observed. The cell densities and viabilities post infection of all cultures at each passage were 239 
determined and no significant difference was observed (Figure 3B). The titers of BV stocks did 240 
not decline with increasing passage number (Table 1) and the observed difference in the effect of 241 
serial passaging is not due to the changes in MOI used. The serial passage of recombinant 242 
baculoviruses in insect cells can lead to the accumulation of replication-defective deletion mutant 243 
viruses known as defective interfering particles (DIPs) [28]. Such accumulated DIPs often lack 244 
the foreign gene of interest, and compete with the normal recombinant baculovirus during 245 
infection. This in turn results in a decrease in recombinant protein production [29, 30]. 246 
Accumulation of DIPs without either or both P1 and 3CD protease genes during the serial 247 
passaging of BV stocks for scale-up production could render this VLP production process 248 
unviable if it is not carefully monitored. 249 
3.3 Effect of virus stock storage on expression 250 
The effect storage stability at 4°C of passage 3 BV stock on the structural protein production of 251 
both EV71 and CVA16 constructs was investigated (Figures 4A and 4B). EV71 and CVA16 252 
structural protein production was analyzed by Western blots, using anti-EV71-VP0 and anti-253 
CVA16-VP0 antibodies, respectively. EV71 passage 3 BV stock retained its ability to infect Sf9 254 
cells leading to comparable structural protein production (Figure 4A) after storage for 4 months 255 
at 4°C. However, a significant reduction in the CVA16 structural protein production was 256 
observed for BV stock stored at 4°C for 4 months (Figure 4B). Given the sensitivity of CAV16 257 
passage 3 BV virus stock to storage at 4°C, freshly amplified passage 3 BV stock from passage 2 258 
BV stock should be used for each production run. Figure 4C shows that CVA16 passage 2 BV 259 
stock maintained better infectivity, thus productivity, when stored at -80°C than at 4°C (Figure 260 
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4C). The freeze-thaw effect on BV infectivity could have caused the slight decrease in structural 261 
proteins, similar to a previous report [31]. 262 
3.4 Purification of EV71 and CVA16 VLPs 263 
EV71 and CVA16 VLPs were expressed in Sf9 cells at 21
o
C for 120 h. Both VLPs were purified 264 
from culture supernatant and cell pellet, separately by Capto™ Core chromatography, and 265 
multiple protein bands were detected on the SDS-PAGE gel analysis (Figure 5A). Three protein 266 
bands corresponding to P1 polyprotein, VP0+VP3 intermediates and VP0 were detected on the 267 
anti-VP0 Western blot analysis (Figure 5B). This confirms that co-expressing P1 polyprotein and 268 
3CD protease resulted in P1 cleavage by 3CD protease and self-assembly of VLPs in insect cells 269 
as previously reported [12]. However, the results also suggest that the purified VLP fractions 270 
may contain P1 polyprotein and partially processed intermediates VP0+VP3. It is possible that 271 
EV71 and CVA16 VLPs produced in insect cells do contain partially processed structural 272 
proteins. Another possibility is unprocessed P1 polyprotein and intermediates VP0+VP3 were 273 
misforming or aggregating into particles larger than 700 kDa, consequently, being excluded from 274 
the Capto™ Core chromatography resin and were co-purified with the assembled VLPs. 275 
 276 
Purification of both VLPs from the cells [32, 33] or culture supernatant [20, 34] has been 277 
reported previously. Chung et al. have purified EV71 VLPs from cells [32] and culture 278 
supernatant [20], and have reported to prefer culture supernatant for ease of purification [20]. 279 
Intracellular VLPs are released either mechanically (homogenization/sonication), chemically or 280 
enzymatically from the cells [35]. During this lysis process, other host cell proteins are released 281 
along with the target VLPs [36], necessitating extra purification processes to purify the VLPs 282 
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away from host contaminants thus increasing production costs. Moreover, the buffer composition 283 
(salt and pH) can drive the VLPs to either aggregate or dissociate during the lysis process, 284 
thereby affecting the structural and colloidal stability of VLPs [10]. In contrast, this extraction 285 
step is completely avoided in extracellular VLP purification, thereby decreasing the number of 286 
steps, time and cost involved in downstream processing [36]. 287 
3.5 Characterization of EV71 and CVA16 VLPs 296 
The first use of AF4-MALS technique for accurately characterizing EV71 and CVA16 VLPs is 297 
demonstrated here (Figures 5C and 5D). The AF4-MALS method for enterovirus VLP 298 
characterization was developed and optimized using EV71 VLP standard, based on a previously 299 
described method [18]. A VLP peak was detected at a retention time of 20 min, and the average 300 
root mean square (rms) radius of EV71 VLP standard was calculated as 15.4 ± 1 nm. A peak at a 301 
retention time of 12 min (likely comprised of proteins) and an aggregate peak at a retention time 302 
greater than 40 min were also observed. This AF4-MALS analytical method was used to 303 
characterize the size and distribution of purified VLPs of EV71 (Figure 5C) and CVA16 (Figure 304 
5D). The average rms radius of EV71 and CVA16 VLPs were calculated as 15 ± 1 nm and 15.3 305 
± 5.8 nm, respectively. As illustrated in Figures 5C and 5D, the heterogeneity of VLP samples 306 
could be detected and characterized using AF4-MALS. The VLP yields calculated from the VLP 307 
peak areas (Peak B) reveal that EV71 VLP yield is 2.7x higher than CVA16. This method allows 308 
quantitative characterization of VLPs in parallel to VLP visualization under TEM (Figure 5E). 309 
The size measurement of both EV71 and CVA16 VLPs by AF4-MALS is consistent with 310 
reported measurements using dynamic light scattering (30 nm diameter) [37]. Unlike the 311 
dynamic light scattering method, AF4-MALS technique allows high resolution of particles based 312 
on size, thus enabling highly accurate particle size determination [18]. 313 
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4. Conclusions 314 
The expression of both EV71 and CVA16 VLPs in insect cells were significantly enhanced by 315 
lowering the temperature of standard 27°C to 21°C. The insect cell line of choice for production 316 
of both VLPs is Sf9 cell line. The CVA16-expressing baculovirus was more susceptible to serial 317 
passage effect in cell culture than EV71. The production of CVA16 structural proteins 318 
diminished after 5 passages in cell culture, potentially a challenge to the large-scale production 319 
of CVA16 VLPs. Higher EV71 VLP yield was obtained from culture supernatant, whereas 320 
higher CVA16 VLP yield was obtained from the cells. These factors will affect the design and 321 
development of production processes for a bivalent EV71 and CVA16 VLP. This study also 322 
reports the first AF4-MALS characterization of EV71 and CVA16 VLPs. The use of high 323 
resolution AF4-MALS, dynamic light scattering and TEM techniques allow biophysical 324 
characterization on VLP integrity, which is critical to the development of VLP vaccines.  325 
 326 
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Figure captions 393 
 394 
Figure 1: Diagrammatic representation of P1 polyprotein processing and assembly of 395 
structural proteins. P1 polyprotein is proteolytically cleaved into intermediate VP0+VP3 and 396 
VP1 proteins. The intermediate VP0+VP3 is further cleaved into VP0 and VP3 proteins. 397 
Structural proteins VP0, VP3 and VP1 first assemble to form a protomer. A pentamer is made of 398 
five protomers and twelve copies of pentamer come together to form a VLP. 399 
 400 
Figure 2: Effect of temperature and cell line on EV71 and CVA16 VLP expression. EV71 401 
and CVA16 VLPs were expressed in Sf9 and High Five
TM
 insect cell lines at 27°C and 21°C. A) 402 
EV71 and CVA16 expression profiles were examined on Western blot analysis using anti-VP1 403 
antibody. EV71 and CVA16 samples harvested at 24, 48, 72 and 96 hours post infection (hpi) 404 
from 27
o
C were analyzed. At 21
o
C, EV71 samples were harvested at 48, 72, 96 and 120 hpi and 405 
CVA16 samples were harvested at 72, 96, 120 and 144 hpi, for analysis. B) CVA16 P1 406 
polyprotein processing in Sf9 insect cells were analyzed by Western blot using anti-CVA16-VP0 407 
antibody. The P1 polyprotein, intermediate VP0+VP3 and VP0 were observed on anti-CVA16-408 
VP0 Western blot. Lanes: M, molecular weight marker; C, uninfected cell control. 409 
 410 
Figure 3: Effect of serial passaging on EV71 and CVA16 VLP expression. A) Analysis of 411 
VP1 expression at different passage number by anti-VP1 Western blot. B) Plots of viable cell 412 
densities of Sf9 cultures at different passage number. 413 
  
 20 
 414 
Figure 4: Effect of storage stability of virus stocks on EV71 and CVA16 VLP expression.  415 
Anti-VP0 western blot analysis on the expression profile of A) EV71, B) CVA16 using passage 416 
3 virus stocks stored at 4°C for 4 months, and C) CA16 VLPs using passage 2 virus stocks stored 417 
at 4°C and -80°C for 4 months.  418 
 419 
Figure 5: Purification and characterization of EV71 and CVA16 VLPs. VLPs from both 420 
intracellular and extracellular fractions were purified. Intracellular VLPs were purified by 421 
ammonium sulphate precipitation followed by Capto
TM
 Core 700 chromatography. Extracellular 422 
VLPs were purified using Capto
TM
 Core 700 chromatography. Purified VLPs were analyzed on 423 
SDS-PAGE (A) and anti-VP0 Western blot (B). C & D) Fractograms from asymmetric flow 424 
field-flow fractionation coupled with multi-angle light scattering of EV71 VLP standard in 425 
comparison with purified VLPs of EV71 (C) and CVA16 (D). Proteins (Peak A), VLPs (Peak B) 426 
and aggregates (Peak C) were separated and detected in the VLP samples. E) Characterization of 427 
VLPs with transmission electron microscopy. 428 
  429 
  
 21 
Table 1: Virus titers of EV71 and CVA16 budded virus stocks. 430 
Passage number EV71 virus titer 
(10
8
 IU/mL) 
CVA16 virus titer 
(10
8 
IU/mL) 
3 2.77 2.77 
4 3.35 2.16 
5 3.65 2.24 
6 3.05 6.25 
7 4.76 6.79 
 431 
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Highlights 
 Expression at 21°C enhanced the production of EV71 and CVA16 VLPs in Sf9 cells 
 CVA16 expression yield is adversely affected by serial passaging of virus 
 Higher VLP yield is obtained with EV71 compared to CVA16 
 VLP size distributions of EV71 and CVA16 VLPs are characterized by AF4-MALS 
